Guided Therapeutics INC 10-Q quarterly reports

Guided Therapeutics, Inc. reported its Q2 2026 financial results, highlighting continued operating losses and a substantial accumulated deficit, while also noting progress in its LuViva device clinical trials and ongoing capital-raising efforts.

Guided Therapeutics, Inc. filed its Q1 2026 Form 10-Q, detailing financial performance, operational updates, and a significant promissory note extension with its CEO.

Guided Therapeutics reported increased net losses and negative working capital, with key regulatory approvals for its LuViva device facing delays in China and potential impacts from a U.S. government shutdown.

Guided Therapeutics reported a widened net loss and deepening accumulated deficit in Q2 2025, highlighting significant liquidity challenges despite progress in regulatory approvals for its LuViva device.

Guided Therapeutics enters into a securities purchase agreement for a $149,500 convertible note to bolster working capital as it navigates commercialization and regulatory pathways for its LuViva device.

Guided Therapeutics reports its Q3 2024 financials, highlighting ongoing efforts in product development and regulatory approvals, while navigating financial challenges.

Guided Therapeutics reports its second quarter 2024 results, highlighting ongoing clinical trials, regulatory efforts, and continued financial challenges.

Guided Therapeutics reports a net loss of $441,000 for the first quarter of 2024, while continuing to focus on clinical trials and international expansion for its LuViva device.